MY168937A - Ethynyl derivatives as modulators of mglur5 receptor activity - Google Patents

Ethynyl derivatives as modulators of mglur5 receptor activity

Info

Publication number
MY168937A
MY168937A MYPI2015000470A MYPI2015000470A MY168937A MY 168937 A MY168937 A MY 168937A MY PI2015000470 A MYPI2015000470 A MY PI2015000470A MY PI2015000470 A MYPI2015000470 A MY PI2015000470A MY 168937 A MY168937 A MY 168937A
Authority
MY
Malaysia
Prior art keywords
modulators
ethynyl derivatives
receptor activity
mglur5 receptor
disease
Prior art date
Application number
MYPI2015000470A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Eric Vieira
Heinz Stadler
Antonio Ricci
Daniel Rueher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY168937A publication Critical patent/MY168937A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2015000470A 2012-10-18 2013-10-15 Ethynyl derivatives as modulators of mglur5 receptor activity MY168937A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12188940 2012-10-18

Publications (1)

Publication Number Publication Date
MY168937A true MY168937A (en) 2019-01-10

Family

ID=47049067

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000470A MY168937A (en) 2012-10-18 2013-10-15 Ethynyl derivatives as modulators of mglur5 receptor activity

Country Status (26)

Country Link
US (1) US9227959B2 (enExample)
EP (1) EP2909180B1 (enExample)
JP (1) JP5989250B2 (enExample)
KR (1) KR101684816B1 (enExample)
CN (1) CN104718192B (enExample)
AR (1) AR093042A1 (enExample)
AU (1) AU2013333988B2 (enExample)
BR (1) BR112015006454A8 (enExample)
CA (1) CA2882520A1 (enExample)
CL (1) CL2015000891A1 (enExample)
CO (1) CO7200248A2 (enExample)
CR (1) CR20150144A (enExample)
EA (1) EA025667B1 (enExample)
ES (1) ES2599553T3 (enExample)
IL (1) IL237380A (enExample)
MA (1) MA38012B1 (enExample)
MX (1) MX2015004898A (enExample)
MY (1) MY168937A (enExample)
NZ (1) NZ705144A (enExample)
PE (1) PE20150629A1 (enExample)
PH (1) PH12015500398A1 (enExample)
SG (1) SG11201501392TA (enExample)
TW (1) TWI490208B (enExample)
UA (1) UA114529C2 (enExample)
WO (1) WO2014060398A1 (enExample)
ZA (1) ZA201500856B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114008C2 (xx) * 2012-10-18 2017-04-10 Похідні етинілу як модулятори активності рецептора mglur5
AU2016273751B2 (en) * 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
EP3353161B1 (en) * 2015-09-25 2021-07-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Triazole derivatives as p2y14 receptor antagonists
RS62517B1 (sr) 2017-12-08 2021-11-30 Boehringer Ingelheim Int Derivati imidazopiridina i njihova upotreba kao leka
EA202191014A1 (ru) * 2018-10-17 2021-11-09 Бёрингер Ингельхайм Интернациональ Гмбх Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
TW202035396A (zh) 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途
CN112888684B (zh) * 2018-10-17 2023-10-10 勃林格殷格翰国际有限公司 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
WO2020245136A1 (en) 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
KR20100033981A (ko) * 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
MA38012B1 (fr) 2016-12-30
BR112015006454A8 (pt) 2019-08-20
HK1207639A1 (zh) 2016-02-05
EP2909180B1 (en) 2016-10-05
MX2015004898A (es) 2015-07-21
CR20150144A (es) 2015-04-30
KR20150055044A (ko) 2015-05-20
WO2014060398A1 (en) 2014-04-24
AU2013333988A1 (en) 2015-02-26
BR112015006454A2 (pt) 2017-07-04
AR093042A1 (es) 2015-05-13
PE20150629A1 (es) 2015-05-11
US20150225385A1 (en) 2015-08-13
ES2599553T3 (es) 2017-02-02
US9227959B2 (en) 2016-01-05
SG11201501392TA (en) 2015-05-28
IL237380A0 (en) 2015-04-30
JP2015531392A (ja) 2015-11-02
KR101684816B1 (ko) 2016-12-20
CO7200248A2 (es) 2015-02-27
EP2909180A1 (en) 2015-08-26
JP5989250B2 (ja) 2016-09-07
TW201420571A (zh) 2014-06-01
NZ705144A (en) 2018-09-28
TWI490208B (zh) 2015-07-01
AU2013333988B2 (en) 2017-03-09
PH12015500398B1 (en) 2015-04-27
CL2015000891A1 (es) 2015-09-11
UA114529C2 (uk) 2017-06-26
PH12015500398A1 (en) 2015-04-27
MA38012A1 (fr) 2016-05-31
EA201590699A1 (ru) 2015-07-30
CA2882520A1 (en) 2014-04-24
IL237380A (en) 2017-02-28
CN104718192A (zh) 2015-06-17
CN104718192B (zh) 2016-08-31
EA025667B1 (ru) 2017-01-30
ZA201500856B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
PH12015500398A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PH12015502692A1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500261A1 (en) Arylethynyl pyrimidines
WO2014100815A3 (en) Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
PH12017502128A1 (en) Ethynyl derivatives
IL202282A0 (en) Prolinamide-tetrazole derivatives as nk3 receptor antagonists
TH167680A (th) อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของฤทธิ์ของ mglur5 รีเซปเตอร์